D. R. Martinez

Broadly neutralizing antibody induction by non-stabilized SARS-CoV-2 Spike mRNA vaccination in nonhuman primates

Non-stabilized SARS-CoV-2 Spike mRNA vaccination in macaques induces B cell lineages targeting conserved epitopes on Omicron variants or cross-neutralizing epitopes on Sarbecoviruses.

Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potential

This study evaluates the antiviral efficacy of GS-5245 against multiple SARS-CoV-2 variants and other coronaviruses, showing broad in vitro activity and protective effects in animal models.

Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease

The paper identifies broadly neutralizing antibodies targeting the S2 region of betacoronavirus spikes that protect against SARS-CoV-1, SARS-CoV-2, and MERS-CoV.

Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH Domains

This study identifies a biparatopic VH domain that neutralizes SARS-CoV-2 VOCs, including Omicron, with high potency in vitro and in a mouse model.

Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine

This study shows a nanoparticle vaccine induces broad neutralizing antibodies against multiple SARS-CoV-2 variants and protects non-human primates and mice from viral challenges.

Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice.

This paper evaluates the therapeutic efficacy of GS-621763, an oral prodrug of remdesivir, against SARS-CoV-2 in mice, showing reduced viral load and improved lung function.

Targeted isolation of panels of diverse human protective broadly neutralizing antibodies against SARS-like viruses

This study isolates a panel of broadly neutralizing antibodies against SARS-like viruses from donors, showing effectiveness against multiple variants including Omicron.

Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice

This study shows chimeric spike mRNA vaccines protect mice against multiple Sarbecovirus strains, including variants and zoonotic viruses, better than standard SARS-CoV-2 vaccines.

Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants

The paper identifies ultrapotent antibodies from convalescent donors that neutralize SARS-CoV-2 variants and reduce escape mutant generation.

SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys

This study shows that SARS-CoV-2 vaccines induce neutralizing antibodies against SARS-CoV-1, SARS-CoV-2, and batCoVs in monkeys.

The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates

This study examines SARS-CoV-2 neutralizing and infection-enhancing antibodies, showing in vitro enhancement does not always lead to in vivo disease enhancement, but can cause increased lung inflammation in monkeys.

Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions

The paper identifies cross-reactive antibodies against multiple coronaviruses, showing they target diverse epitopes and mediate effector functions.

LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection

LY-CoV555, an anti-spike antibody from a convalescent COVID-19 patient, neutralizes SARS-CoV-2 and protects non-human primates against infection.

SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness

This paper describes the development of an mRNA vaccine (mRNA-1273) against SARS-CoV-2, showing it induces neutralizing antibodies and CD8 T cell responses and protects mice from infection.

Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals

The paper identifies potent neutralizing antibodies against SARS-CoV-2 that block receptor binding and protect animals, providing insights for vaccine and therapy development.

Rapid selection of a human monoclonal antibody that potently neutralizes SARS-CoV-2 in two animal models

This study rapidly identifies a potent human monoclonal antibody against SARS-CoV-2 that neutralizes the virus in animal models and shows promise for therapeutic use.

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

This study isolates and profiles human monoclonal antibodies against SARS-CoV-2 spike protein, identifying neutralizing antibodies targeting the receptor-binding domain.

A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures

This paper develops a mouse-adapted SARS-CoV-2 model to evaluate medical countermeasures, showing age-related disease severity and the efficacy of IFN lambda-1a.

Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice.

This study shows remdesivir effectively inhibits SARS-CoV-2 in human cells and mice, reducing viral load and improving lung function.

IgG is differentially and selectively transferred across the placenta in HIV-infected women

This study identifies factors affecting placental IgG transfer efficiency in HIV-infected women, showing that maternal disease progression and Fc region characteristics influence selective transfer of antigen-specific IgG.